Ascendis Pharma A/S (ASND) News Today $165.25 -2.74 (-1.63%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by BrokeragesShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and thirteen have issMarch 25 at 5:11 AM | marketbeat.comSei Investments Co. Sells 10,165 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Sei Investments Co. lowered its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,582 shares of the biotechnology company'sMarch 25 at 4:40 AM | marketbeat.comThrivent Financial for Lutherans Decreases Position in Ascendis Pharma A/S (NASDAQ:ASND)Thrivent Financial for Lutherans reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 54.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,941 shares of the biotechnology company's stock afterMarch 25 at 3:54 AM | marketbeat.comProficio Capital Partners LLC Acquires New Position in Ascendis Pharma A/S (NASDAQ:ASND)Proficio Capital Partners LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,528 shares of the biotechnology companMarch 20, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday.March 19, 2025 | marketbeat.comAscendis Pharma price target raised to $200 from $168 at JPMorganMarch 19, 2025 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Ascendis Pharma (ASND)March 18, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Reaches New 52-Week High - Time to Buy?Ascendis Pharma A/S (NASDAQ:ASND) Reaches New 12-Month High - Still a Buy?March 18, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Bank of New York Mellon CorpBank of New York Mellon Corp lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 98,392 shares of the biotechnology company's stock afterMarch 13, 2025 | marketbeat.comVictory Capital Management Inc. Sells 2,505 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Victory Capital Management Inc. decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 131,353 shares of the biotechnology company's stock after selling 2,505 shares during the peMarch 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Candriam S.C.A.Candriam S.C.A. decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 280,154 shares of the biotechnology company's stockMarch 7, 2025 | marketbeat.com12,528 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Proficio Capital Partners LLCProficio Capital Partners LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,528 shares of the biotechnology company's stock, valued at approximately $1March 7, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Ascendis Pharma (ASND)March 5, 2025 | markets.businessinsider.comHenry James International Management Inc. Trims Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Henry James International Management Inc. decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,851 shares of the biotechnology comMarch 2, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - Here's WhyAscendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - What's Next?March 1, 2025 | marketbeat.comCantor Fitzgerald Comments on ASND FY2025 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued on Tuesday, February 25th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnolFebruary 28, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommFebruary 28, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Handelsbanken Fonder ABHandelsbanken Fonder AB lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 22.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 13,667 shares of the biotechnology company's stock after selling 4,000 shares during the period. HandelsbankenFebruary 26, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00 at Cantor FitzgeraldCantor Fitzgerald lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday.February 25, 2025 | marketbeat.comAscendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | markets.businessinsider.comAscendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comNew York State Common Retirement Fund Acquires 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)New York State Common Retirement Fund boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 204,482 shares of the biotechnology company's stock aFebruary 21, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISIEvercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday.February 19, 2025 | marketbeat.comAscendis Pharma price target raised to $180 from $175 at Morgan StanleyFebruary 18, 2025 | markets.businessinsider.comRice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Rice Hall James & Associates LLC raised its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 163,888 shares of the biotechnologFebruary 18, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Outlook for ASND EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at Leerink Partnrs lifted their Q1 2025 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Wednesday, February 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnolFebruary 17, 2025 | marketbeat.comQ1 EPS Estimates for Ascendis Pharma A/S Lowered by WedbushAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Wedbush reduced their Q1 2025 earnings per share estimates for Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earningFebruary 17, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Trims Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)Allspring Global Investments Holdings LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,738 shares of the biotechnologFebruary 16, 2025 | marketbeat.comWhat is Wedbush's Forecast for ASND FY2029 Earnings?Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Wedbush lifted their FY2029 earnings per share estimates for shares of Ascendis Pharma A/S in a report released on Wednesday, February 12th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will earn $14.13 per share for the yFebruary 15, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?February 15, 2025 | finance.yahoo.comQ4 2024 Ascendis Pharma A/S Earnings Call TranscriptFebruary 13, 2025 | gurufocus.comAscendis Pharma A/S Earnings Call Highlights Growth and ChallengesFebruary 13, 2025 | tipranks.comAscendis Pharma price target lowered to $192 from $203 at BofAFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma price target raised to $162 from $153 at TD CowenFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from J.P. MorganFebruary 13, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $225.00 at The Goldman Sachs GroupThe Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given New $168.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Up on Better-Than-Expected EarningsAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Up on Strong EarningsFebruary 13, 2025 | marketbeat.comAscendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025February 13, 2025 | seekingalpha.comAscendis Pharma A/S (ASND) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comAscendis Pharma announces share repurchase program, settlement of certain RSUsFebruary 12, 2025 | markets.businessinsider.comAscendis Pharma reports Q4 EPS (EUR 0.64) vs (EUR 1.53) last yearFebruary 12, 2025 | markets.businessinsider.comEarnings call transcript: Ascendis Pharma Q4 2024 sees revenue riseFebruary 12, 2025 | msn.comAscendis Pharma launches $25 million share buybackFebruary 12, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results, Beats Estimates By $0.64 EPSAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64.February 12, 2025 | marketbeat.comAscendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUsFebruary 12, 2025 | globenewswire.comAscendis Pharma Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 12, 2025 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday.February 11, 2025 | marketbeat.comMorgan Stanley Remains a Hold on Ascendis Pharma (ASND)February 10, 2025 | markets.businessinsider.com Remove Ads Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.580.63▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼96▲ASND Articles Average Week Remove Ads Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARGX News Today ONC News Today BNTX News Today TEVA News Today SMMT News Today ITCI News Today MRNA News Today GMAB News Today RDY News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
